The multinational pharmaceutical giant Lupin Limited (Lupin) declared that it has obtained the US Food and Drug Administration’s (US FDA) Establishment Inspection Report (EIR) for drug-medical device combination products at its injectable facility in Nagpur, India. After a facility inspection that took place between June 10 and June 13, 2024, the EIR was released.

“We are delighted to have received the EIR from the US FDA for drug-device combination products at our injectable facility in Nagpur. We are still dedicated to creating necessary and sophisticated generic goods that fill gaps in the market” said Nilesh Gupta, Managing Director of Lupin.

A great achievement indeed.

Priyanka Dutta